As you might know, Intellia Therapeutics, Inc. (NASDAQ:NTLA) last week released its latest second-quarter, and things did not turn out so great for shareholders. It was not a great statutory result, with revenues coming in 64% lower than the analysts predicted. Unsurprisingly, earnings also fell seriously short of forecasts, turning into a per-share loss of US$1.52. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on Intellia Therapeutics after the latest results.

View our latest analysis for Intellia Therapeutics

Following the latest results, Intellia Therapeutics' 23 analysts are now forecasting revenues of US$58.8m in 2024. This would be a substantial 28% improvement in revenue compared to the last 12 months. Per-share losses are predicted to creep up to US$5.57. Yet prior to the latest earnings, the analysts had been forecasting revenues of US$68.5m and losses of US$5.12 per share in 2024. So there's been quite a change-up of views after the recent consensus updates, withthe analysts making a serious cut to their revenue outlook while also expecting losses per share to increase.

The average price target was broadly unchanged at US$69.84, perhaps implicitly signalling that the weaker earnings outlook is not expected to have a long-term impact on the valuation. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. Currently, the most bullish analyst values Intellia Therapeutics at US$144 per share, while the most bearish prices it at US$24.00. So we wouldn't be assigning too much credibility to analyst price targets in this case, because there are clearly some widely different views on what kind of performance this business can generate. As a result it might not be a great idea to make decisions based on the consensus price target, which is after all just an average of this wide range of estimates.

These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Intellia Therapeutics' past performance and to peers in the same industry. The analysts are definitely expecting Intellia Therapeutics' growth to accelerate, with the forecast 63% annualised growth to the end of 2024 ranking favourably alongside historical growth of 1.8% per annum over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 23% per year. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect Intellia Therapeutics to grow faster than the wider industry.